Advertisement

Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker?

  • Taher Mandviwala
  • Umair Khalid
  • Anita Deswal
Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Coronary Heart Disease

Abstract

In the USA, 69 % of adults are either overweight or obese and 35 % are obese. Obesity is associated with an increased incidence of various cardiovascular disorders. Obesity is a risk marker for cardiovascular disease, in that it is associated with a much higher prevalence of comorbidities such as diabetes, hypertension, and metabolic syndrome, which then increase the risk for cardiovascular disease. However, in addition, obesity may also be an independent risk factor for the development of cardiovascular disease. Furthermore, although obesity has been shown to be an independent risk factor for several cardiovascular diseases, it is often associated with improved survival once the diagnosis of the cardiovascular disease has been made, leading to the term “obesity paradox.” Several pathways linking obesity and cardiovascular disease have been described. In this review, we attempt to summarize the complex relationship between obesity and cardiovascular disorders, in particular coronary atherosclerosis, heart failure, and atrial fibrillation.

Keywords

Obesity Cardiovascular disease Hypertension Atherosclerosis Coronary artery disease Heart failure 

Notes

Compliance with Ethical Standards

Conflict of Interest

Taher Mandviwala and Umair Khalid declare that they have no conflict of interest.

Anita Deswal declares research support from Novartis as site-PI of multicenter clinical trial, and grant support from the NIH as site-PI for clinical trials.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Flegal K, Carroll M, Kit B, Ogden C. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307:491–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Fontaine K, Redden D, Wang C, Westfall A, Allison D. Years of life lost due to obesity. JAMA. 2003;289:187–93.CrossRefPubMedGoogle Scholar
  3. 3.
    Poirier P, Giles T, Bray G, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006;113:898–918.CrossRefPubMedGoogle Scholar
  4. 4.
    Poirier P, Martin J, Marceau P, Biron S, Marceau S. Impact of bariatric surgery on cardiac structure, function and clinical manifestations in morbid obesity. Expert Rev Cardiovasc Ther. 2004;2:193–201.CrossRefPubMedGoogle Scholar
  5. 5.
    Horwich TB, Fonarow GC, Hamilton M, MacLellan W, Woo M, Tillisch J. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789–95.CrossRefPubMedGoogle Scholar
  6. 6.•
    Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1(2):93–102. Lavie et al. review the data on obesity and cardiopulmonary fitness in heart failure patients. The article also includes informative data on obesity and its impact on treatments such as heart transplantation and LV assist devices.CrossRefPubMedGoogle Scholar
  7. 7.
    Shah R, Gayat E, Januzzi Jr JL, et al. Mebazaa A Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol. 2014;63:778–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Akin I, Nienaber C. “Obesity paradox” in coronary artery disease. World J Cardiol. 2015;7(10):603–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report: National Institutes of Health. Obes Res. 1998;2:51S–209S.Google Scholar
  10. 10.
    Kurpad SS, Tandon H, Srinivasan K. Waist circumference correlates better with body mass index than waist-to-hip ratio in Asian Indians. Natl Med J India. 2003;16(4):189–92.PubMedGoogle Scholar
  11. 11.•
    Rocha V, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6:399–409. Rocha et al. review in detail the interplay between obesity and inflammation leading to the development of atherosclerosis.CrossRefPubMedGoogle Scholar
  12. 12.
    Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115–26.CrossRefPubMedGoogle Scholar
  13. 13.
    Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289:1799–804.CrossRefPubMedGoogle Scholar
  14. 14.
    Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Ridker P. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129–38.CrossRefPubMedGoogle Scholar
  16. 16.
    Everett B, Kurth T, Buring J, Ridker P. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol. 2006;48:2235–42.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ridker P, Stampfer M, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285(19):2481–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.CrossRefPubMedGoogle Scholar
  19. 19.
    Visser M, Bouter L, McQuillan G, Wener M, Harris T. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Pearson T, Mensah G, Alexander R, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.CrossRefPubMedGoogle Scholar
  21. 21.
    Ridker P, Rifai N, Pfeffer M, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CAre) investigators. Circulation. 1998;98:839–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Ridker P, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–65.CrossRefPubMedGoogle Scholar
  23. 23.
    Ridker P, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.CrossRefPubMedGoogle Scholar
  24. 24.
    Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of ikkbeta. Science. 2001;293:1673–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Fleischman A, Shoelson S, Bernier R, Goldfine A. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31:289–94.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Koska J, Ortega E, Bunt J, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia. 2009;52:385–93.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wolk R, Berger P, Lennon J, Brilakis E, Somers V. Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation. 2003;108:2206–11.CrossRefPubMedGoogle Scholar
  28. 28.
    McGill H, McMahan C, Herderick E, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105:2712–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Rabkin S, Mathewson F, Hsu P. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol. 1977;39:452–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Manson J, Colditz G, Stampfer M, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322:882–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Wilson P, D’Agostino R, Sullivan L, Parise H, Kannel W. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;16:1867–72.CrossRefGoogle Scholar
  32. 32.
    Din-Dzietham R, Liu Y, Bielo M, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. 2007;116(13):1488–96.CrossRefPubMedGoogle Scholar
  33. 33.
    Lau D, Dhillon B, Yan H, Szmitko P, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288:2031–41.CrossRefGoogle Scholar
  34. 34.
    Juge-Aubry C, Henrichot E, Meier C. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005;19:547–66.CrossRefPubMedGoogle Scholar
  35. 35.
    Knudson J, Dincer U, Zhang C, et al. Leptin receptors are expressed in coronary arteries and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2005;289:48–56.CrossRefGoogle Scholar
  36. 36.
    Trayhurn P, Wood I. Signaling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans. 2005;33:1078–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Payne G, Kohr M, Tune J. Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease. Br J Pharmacol. 2012;165(3):659–69.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis. 2009;19:440–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Salama M, Morad A, Saleh M, Sabri N, Zaki M, ElSafady L. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. J Clin Pharm Ther. 2012;37:630–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Kragelund C, Hassager C, Hildebrandt P, Torp-Pedersen C, Kober L. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol. 2005;98:123–31.CrossRefPubMedGoogle Scholar
  41. 41.
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364:937–52.CrossRefPubMedGoogle Scholar
  42. 42.
    Madala M, Franklin B, Chen A, et al. Obesity and age of first non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;52:979–85.CrossRefPubMedGoogle Scholar
  43. 43.
    Das S, Alexander K, Chen A, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data). J Am Coll Cardiol. 2011;58(25):2642–50.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Bajaj S, Shamoon F, Gupta N, et al. Acute ST-segment elevation myocardial infarction in young adults: who is at risk? Coron Artery Dis. 2011;22:238–44.CrossRefPubMedGoogle Scholar
  45. 45.
    Jamil G, Jamil M, Alkhazraji H, et al. Risk factor assessment of young patients with acute myocardial infarction. Am J Cardiovasc Dis. 2013;3:170–4.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Lavie C, Milani R, Ventura H. Obesity and cardiovascular disease: risk factor, paradox and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–32.CrossRefPubMedGoogle Scholar
  47. 47.
    Nikolsky E, Kosinski E, Mishkel GJ, et al. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol. 2005;95:709–15.CrossRefPubMedGoogle Scholar
  48. 48.
    Sarno G, Garg S, Onuma Y, et al. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with biolimus- and sirolimus-eluting stents (from the LEADERS Trial). Am J Cardiol. 2010;105:475–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Sarno G, Raber L, Onuma Y, et al. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents. Am J Cardiol. 2011;108:195–201.CrossRefPubMedGoogle Scholar
  50. 50.
    Akin I, Tolg R, Hochadel M, et al. No evidence of “obesity paradox” after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. JACC Cardivasc Interv. 2012;5(2):162–9.CrossRefGoogle Scholar
  51. 51.
    Wang Z, Zhou Y, Zhao Y, et al. Effect of obesity on repeat revascularization in patients undergoing percutaneous coronary intervention with drug-eluting stents. Obesity (Silver Spring). 2012;20:141–6.CrossRefGoogle Scholar
  52. 52.
    Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol. 2007;120:188–92.CrossRefPubMedGoogle Scholar
  53. 53.
    Mahaffey K, Tonev S, Spinler S, et al. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010;139:123–33.CrossRefPubMedGoogle Scholar
  54. 54.
    Kadakia M, Fox C, Scirica B, Murphy S, Bonaca M, Morrow D. Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Heart. 2011;97:1782–7.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Oreopoulos A, Padwal R, Norris C, Mullen J, Pretorius V, Kalantar-Zadeh K. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity (Silver Spring). 2008;16:442–50.CrossRefGoogle Scholar
  56. 56.
    Li Y, Lin G, Lin C, Wang J, Han C. Relation of body mass index to mortality among patients with percutaneous coronary intervention longer than 5 years follow-up: a meta-analysis. Int J Cardiol. 2013;168:4315–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Bui A, Horwich T, Fonarow G. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Counihan T. Heart failure due to extreme obesity. Br Heart J. 1956;18(3):425–6.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70(9):921–4.CrossRefPubMedGoogle Scholar
  60. 60.
    Kenchaiah S, Evans J, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.CrossRefPubMedGoogle Scholar
  61. 61.
    Kenchaiah S, Sesso H, Gaziano J. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2009;119(1):44–52.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Loehr L, Rosamond W, Poole C, et al. Association of multiple anthropometrics of overweight and obesity with incident heart failure: the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2009;2(1):18–24.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Hu G, Jousilahti P, Antikainen R, Katzmarzyk PT, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121(2):237–44.CrossRefPubMedGoogle Scholar
  64. 64.
    Hu G, Jousilahti P, Antikainen R, Katzmarzyk P, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121:237–44.CrossRefPubMedGoogle Scholar
  65. 65.
    Pascual M, Pascual D, Soria F, et al. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart. 2003;89(10):1152–6.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Alpert M, Alexander J. Obesity and ventricular function in man: systolic function. In: Alpert MA, Alexander JK, editors. The heart and lung in obesity. Armonk, New York: Futura Publishing Company; 1998. p. 77–94.Google Scholar
  67. 67.
    Alexander J, Dennis E, Smith W, Amad K, Duncan W, Austin R. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull. 1962;1:39–44.PubMedGoogle Scholar
  68. 68.
    Alpert M, Lambert C, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol. 1995;76:1194–7.CrossRefPubMedGoogle Scholar
  69. 69.
    Nakajima T, Fujioka S, Tokunaga K, Hirobe K, Matsuzawa Y, Tarui S. Noninvasive study of left ventricular performance in obese patients: influence of duration of obesity. Circulation. 1985;71:481–6.CrossRefPubMedGoogle Scholar
  70. 70.
    McGavock J, Victor R, Unger R, Szczepaniak L. Adiposity of the heart, revisited. Ann Intern Med. 2006;144:517–24.CrossRefPubMedGoogle Scholar
  71. 71.
    Poirier P, Giles T, Bray G, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968–76.CrossRefPubMedGoogle Scholar
  72. 72.
    Kapoor J, Heidenreich P. Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. Am Heart J. 2010;159:75–80.CrossRefPubMedGoogle Scholar
  73. 73.
    Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998–1005.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Ingelsson E, Sundstrom J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294(3):334–41.CrossRefPubMedGoogle Scholar
  75. 75.
    Wannamethee S, Shaper A, Whincup P, Lennon L, Sattar N. Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role? J Am Coll Cardiol. 2011;58:1870–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Frankel D, Vasan R, D’Agostino R, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol. 2009;53(9):754–62.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Bahrami H, Bluemke D, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;51(18):1775–83.CrossRefPubMedGoogle Scholar
  78. 78.
    Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J. 2005;150(6):1233–9.CrossRefPubMedGoogle Scholar
  79. 79.
    Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756–62.CrossRefPubMedGoogle Scholar
  80. 80.•
    Khalid U, Ather S, Bavishi C, et al. Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol. 2014;64(25):2743–9. This is the first study that describes the obesity paradox in heart failure, based on pre-heart failure (i.e. premorbid) BMI. The authors found that obesity and underweight compared to normal weight prior to the development of heart failure was associated with improved survival after the development of heart failure.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Lavie C, Ventura H. Weighing in on obesity and the obesity paradox in heart failure. J Card Fail. 2011;17:381–3.CrossRefPubMedGoogle Scholar
  82. 82.
    Blogowski W, Serwin K, Budkowska M, et al. Clinical analysis of systemic and adipose tissue levels of selected hormones/adipokines and stromal-derived factor-1. J Biol Regul Homeost Agents. 2012;26:607–15.PubMedGoogle Scholar
  83. 83.
    Vest A, Wu Y, Hachamovitch R, Young J, Cho L. The heart failure overweight/obesity survival paradox: the missing sex link. J Am Coll Cardiol HF. 2015;3:917–26.Google Scholar
  84. 84.
    Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:147–239.CrossRefGoogle Scholar
  85. 85.
    Wang T, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471–7.CrossRefPubMedGoogle Scholar
  86. 86.
    Frost L, Benjamin E, Fenger-Grøn M, Pedersen A. Tjønneland A, Overvad K. Body fat, body fat distribution, lean body mass, and atrial fibrillation and flutter. A Danish cohort study. Obesity (Silver Spring). 2014;22:1546–52.CrossRefGoogle Scholar
  87. 87.
    Wanahita N, Messerli F, Bangalore S, Gami A, Somers V, Steinberg J. Atrial fibrillation and obesity: results of a meta-analysis. Am Heart J. 2008;155:310–5.CrossRefPubMedGoogle Scholar
  88. 88.
    Iacobellis G, Ribaudo M, Leto G, et al. Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. Obes Res. 2002;10:767–73.CrossRefPubMedGoogle Scholar
  89. 89.
    Gottdiener J, Reda D, Williams D, Materson B. Left atrial size in hypertensive men: influence of obesity, race and age. J Am Coll Cardiol. 1997;29:651–8.CrossRefPubMedGoogle Scholar
  90. 90.•
    Goudis C, Korantzopoulos P, Ntalas I, Kallergis E, Ketikoglou D. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015;66(5):361–9. Goudis et al. review the most recent clinical and experimental studies linking obesity to atrial fibrillation.CrossRefPubMedGoogle Scholar
  91. 91.
    Yang W, Xu L, Zhang H. Association of CETP and CRP gene polymorphisms with non-valvular atrial fibrillation in Chinese Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008;25:225–229.Google Scholar
  92. 92.
    Kang Y, Hu Y, Li N. Advances in research on G protein-coupled inward rectifier K(+) channel gene. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2012;34:426–430.Google Scholar
  93. 93.
    Rabkin S. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis. Metab Syndr Relat Disord. 2014;12:31–42.CrossRefPubMedGoogle Scholar
  94. 94.
    Thanassoulis G, Massaro J, O’Donnell CJ, et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm E. 2010;3(4):345–50.CrossRefGoogle Scholar
  95. 95.
    Al Chekakie M, Welles C, Metoyer R, et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol. 2010;56:784–8.CrossRefPubMedGoogle Scholar
  96. 96.
    Wong C, Abed H, Molaee P, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011;57(17):1745–51.CrossRefPubMedGoogle Scholar
  97. 97.
    Shin S, Yong H, Lim H, et al. Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(6):647–55.CrossRefPubMedGoogle Scholar
  98. 98.
    Hatem S, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res. 2014;102:205–13.CrossRefPubMedGoogle Scholar
  99. 99.
    Guo Y, Lip G, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263–70.CrossRefPubMedGoogle Scholar
  100. 100.
    Mahajan R, Brooks A, Shipp N. Epicardial fat infiltration of atrial musculature creates the substrate for atrial fibrillation in obesity. Heart Rhythm. 2012;9:124.Google Scholar
  101. 101.
    Zuk P, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279–95.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Pathak R, Middeldorp M, Meredith M, Mehta A, MActSt, Mahajan R, Wong C, Twomey D, Elliott A, Kalman J, Abhayaratna W, Lau D, Sanders P. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015;65:2159–2169Google Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2016

Authors and Affiliations

  1. 1.Baylor College of MedicineHoustonUSA
  2. 2.Michael E. DeBakey VA Medical CenterHoustonUSA

Personalised recommendations